Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock

Area of Science:

• Immunology
• Molecular Biology
• Pathology

Background:

• Triggering receptor expressed on myeloid cell type 1 (TREM-1) amplifies inflammatory responses, potentially contributing to sepsis hyperresponsiveness.
• TREM-1 is expressed on neutrophils and monocytes, key players in the innate immune response to infection.

Purpose of the Study:

• To investigate the therapeutic potential of modulating the TREM-1 pathway in experimental sepsis.
• To evaluate the efficacy of synthetic TREM-1 peptides in preclinical sepsis models.

Main Methods:

• Utilized analogue synthetic peptides derived from the extracellular domain of TREM-1.
• Administered peptides in experimental murine sepsis and peritonitis models.
• Assessed hemodynamic status, lactic acidosis, cytokine production, and survival in septic rats.

Main Results:

• TREM-1 peptides inhibited TREM-1 ligand recognition and protected mice from endotoxin-induced death.
• In septic rats, peptides improved hemodynamics, reduced lactic acidosis, and modulated pro-inflammatory cytokines (TNF-α, IL-1β).
• Peptide treatment improved survival rates in septic rats, partly via decreased nitric oxide production.

Conclusions:

• In vivo modulation of the TREM-1 pathway using synthetic peptides demonstrates significant therapeutic potential for sepsis.
• TREM-1 targeted peptides represent a promising novel therapeutic strategy for managing sepsis and its associated complications.